Dua Kamal, PhD


Faculty of Pharmacy & Pharmaceutical Sciences


Area of Study / Keywords

Nanotechnology Pharmacology and Pharmaceutical Sciences Inflammation Immunology Respiratory diseases


Dr Kamal Dua holds two doctoral degrees (Pharmaceutical Sciences and Immunology and Microbiology), MPharm (with a Major in Pharmaceutics), and BPharm degree. Dr Dua has also completed four professional diplomas in the areas of Clinical Research, Product Development, Drug Regulatory Affairs and Documentation and Intellectual Property Rights (IPR). Dr Dua's professional experience spans over 13 years in academia and research across 3 nations and 2 continents. Dr Dua is currently a full-time associate professor with the Graduate School of Health (Pharmacy), University of Technology Sydney and now lead the suite of GMP courses offered at the Graduate School of Health, UTS. In the past Dr. Dua has been actively involved with Dr Michael John Rathbone, former Professor and Dean, School of Pharmacy, International Medical University (IMU), Malaysia on various pharmacy research projects. This ongoing relationship has now transformed into an industrial linkage where Dr. Dua is involved as a consultant on quality systems management and GMP matters for ULTI Pharmaceuticals, Dr Rathbone’s New Zealand based animal health drug delivery technology company. Dr Dua is also a Conjoint Lecturer with the School of Biomedical Sciences and Pharmacy, The University of Newcastle, Australia.


Dr Dua has a multi-faceted research background with experience in drug delivery technology, biomedical sciences, immunology and microbiology. He is a pharmaceutical and formulation scientist who recognised that there was limited information linking knowledge acquired from various biological (cellular and molecular) approaches to drug delivery. This observation encouraged him to pursue research studies in the field of immunology and microbiology to enhance his ability to bridge the gap between formulation sciences and biological advances. Being a highly focussed and motivated researcher, Dr Dua’s career is dedicated to improving outcomes in healthcare through his initiatives in the formulation and biomedical research.

His dual doctorate “Pharmaceutical Sciences (2010) and Immunology & Microbiology (2018)” enable him to confidently lead cross-disciplinary research in pharmaceutical drug delivery and biological sciences. Dr Dua's research involves identifying potential key targets regulating the pathophysiology of disease and formulating them into effective drug delivery systems that could be translated to clinical settings, thereby contributing to an impactful change. To date, his research has resulted in 190 peer-reviewed publications in various reputed pharmacy and pharmacology journals with total citations of exceeding 17,000. Dr Dua has presented his research findings at numerous (>100) national and international conferences. Moreover, Dr Dua has also published 19 book chapters and 2 books with reputed publishers aligning with his research interests including drug delivery, pathophysiological mechanisms underlying respiratory diseases, and cancer.

His research has influenced the field of drug delivery by sparking recognition of encapsulating potential therapeutic moieties and biomolecules into vesicular drug delivery systems to target inflammatory conditions, with a special emphasis on respiratory diseases [J Drug Deliv Sci Technol (2023); Nutrients (2023); Pharmaceutics (2022); Environ Sci Pollut Res Int (2022); Int J Pharm (2022); Drug Discov Today (2022); Life Sci (2021); Assay Drug Dev Technol (2021); Cancers (2020); Expert Opin. Drug Deliv. (2020); Mater. Sci. Eng. C (2020); J. Microencapsul (2020); Toxicol in vitro (2020); Int. J. Biol. Macromol. (2019); J. Photochem. Photobiol. B (2019); Drug Deliv. Transl. Res. (2018); Pharm. Nanotechnol (2018)].

Dr. Dua's overall skills and expertise in formulation development combined with his in-depth knowledge of immunology enables him to further advance his research with herbal moieties and to explore new avenues and opportunities to expand this area of his pharmaceutical research. As a result, Dr Dua and his team, is actively pursuing their research interests in encapsulating various phytoconstituents in vesicular drug delivery systems to target inflammation in many disease states including airway diseases [Agarwood (Nutrients, 2023); Berberine (Naunyn Schmiedebergs Arch Pharmacol, 2023; Environ Sci Pollut Res Int, 2022; Antioxidants, 2022; Pharmaceutics, 2022), Zerumbone (Naunyn-Schmiedeb. Arch. Pharmacol., 2023), Curcumin (Curr Pharm Design, 2020; Nanomedicine, 2020; Colloids Surf B Biointerfaces, 2018), Rutin (Toxicol in vitro, 2020; Future Med Chem, 2021; Life Sci, 2021), Celastrol (Int. J. Polym. Mater, 2020; Biomed Pharmacother, 2019), Naringenin (J Food Biochem., 2021; Eur J Pharmacol, 2020), Boswellic acid (Future Med Chem, 2020); Tragia involucrata (Antiinflamm Antiallergy Agents Med Chem, 2021); Lens Culinaris Medik. (Curr Pharm Design, 2021).